Anoro is manufactured by GlaxoSmithKline (GSK) and Pfizer [1].
What is Anoro Ellipta used for?
Anoro Ellipta is a medication used for the long-term, once-daily maintenance treatment of bronchospasm and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) [1].
How does Anoro Ellipta work?
Anoro Ellipta contains two active ingredients: umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta2-adrenergic agonist (LABA) [1]. Umeclidinium works by relaxing the muscles around the airways in the lungs, making it easier to breathe. Vilanterol also helps to relax airway muscles. Together, these actions help to open up the airways [1].
When does Anoro Ellipta's patent protection end?
The patent exclusivity for Anoro Ellipta varies by region and specific patents. Information on patent expiry dates can be found on DrugPatentWatch.com [2]. For example, some sources indicate that key patents for umeclidinium bromide and vilanterol trifenatate have expiration dates in the coming years, potentially opening the door for generic versions [2].
What are the alternatives to Anoro Ellipta for COPD?
Other COPD treatments include different combinations of bronchodilators (LAMAs, LABAs), inhaled corticosteroids (ICS), or combinations of these [3]. These may include medications like Spiriva (tiotropium), Symbicort (budesonide/formoterol), or Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) [3]. The choice of treatment depends on the individual patient's needs, disease severity, and response to medication [3].
What are the potential side effects of Anoro Ellipta?
Common side effects reported with Anoro Ellipta include nasopharyngitis (common cold symptoms), diarrhea, cough, and chest pain [1]. More serious, but less common, side effects can include paradoxical bronchospasm, cardiovascular effects, and hypersensitivity reactions [1]. Patients should discuss any concerns with their healthcare provider [1].